Agency Forms Undergoing Paperwork Reduction Act Review, 61327-61329 [2022-22025]
Download as PDF
<![CDATA[
61327
Federal Register / Vol. 87, No. 195 / Tuesday, October 11, 2022 / Notices
Submitted for Public Comment and
Recommendations’’ notice on June 17th,
2022 to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Pilot Plan for the Interim Local Health
Department Strategy for Response,
Control, and Prevention of Healthcare
Associated Infections (HAI) and
Antibiotic Resistance (AR)—New—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Through piloting the Interim Local
Strategy, CDC’s Division of Healthcare
Quality Promotion (DHQP) aims to
understand Local Health Departments’
(LHDs) experience implementing the
strategy and collect their feedback for
refinement. A secondary goal of this
study is to create a network of LHDs
working in Healthcare Associated
Infections (HAI) and Antibiotic
Resistance (AR) activities to learn from
one another and share best practices.
Data collected during the pilot will be
used to assess the extent to which the
strategy materials and resources help
LHDs to: (1) grow and expand their
HAI/AR partner networks and
collaboration; (2) build operational
capacity to conduct and promote
sustainable HAI/AR infection
prevention and control practices; and
(3) expand HAI/AR infection
prevention, outbreak response, and
stewardship activities. Furthermore,
data will inform any necessary
refinements of the materials and
resources.
CDC will conduct data collection
through interviews and electronic
surveys, to capture feedback on the
strategy’s usability and effectiveness, as
well as on each individual material and
resource. CDC will use a mixed methods
approach with both deductive and
inductive analysis of qualitative data
collected through surveys and
structured interviews, and aggregate
quantitative survey data.
CDC requests OMB approval for an
estimated 360 annualized burden hours.
There is no cost to respondents other
than their time to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Average
burden per
response
(in hours)
Form name
Voluntary LHD Participants/NACCHO Coag
LHD participants.
Voluntary LHD Participants .............................
NACCHO CoAg LHD Participants ..................
LHD HAI/AR Strategy Pilot Feedback Form ..
60
1
4
LHD HAI/AR Strategy Pilot Interview Guide ..
LHD HAI/AR Strategy Pilot Survey ................
30
30
1
1
2
2
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–22028 Filed 10–7–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
[30Day–23–22CX]
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
Type of respondents
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Preferences for
Longer-Acting Preexposure Prophylaxis
(PrEP) Methods Among Persons in US
VerDate Sep<11>2014
17:37 Oct 07, 2022
Jkt 259001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Populations at Highest Need: A Discrete
Choice Experiment’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on March 2,
2022, to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
E:\FR\FM\11OCN1.SGM
11OCN1
61328
Federal Register / Vol. 87, No. 195 / Tuesday, October 11, 2022 / Notices
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
khammond on DSKJM1Z7X2PROD with NOTICES
Preferences for Longer-Acting
Preexposure Prophylaxis (PrEP)
Methods Among Persons in US
Populations at Highest Need: A Discrete
Choice Experiment—New—National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention (NCHHSTP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The 2022–2025 National HIV/AIDS
Strategy includes a goal of increasing
PrEP coverage to 50% among persons
with indications, from a 2017 baseline
VerDate Sep<11>2014
17:37 Oct 07, 2022
Jkt 259001
of 13.2%. Despite successes in
development and scale up of daily oral
pre-exposure prophylaxis (PrEP) as a
biomedical HIV prevention product,
studies consistently show obstacles to
its uptake and continuation. The
Centers for Disease Control and
Prevention (CDC) and its partners must
engage in early planning for the
implementation of longer-acting (LA)PrEP agents to help achieve the U.S.
Ending the HIV Epidemic (EHE) goal of
reducing incident HIV infections by
90% by 2030. Understanding providers’
and priority populations’ preferences for
different LA-PrEP agents and perceived
advantages and disadvantages of each
product will be critical to estimating
future uptake and market share of the
various products that are likely to come
to market.
The goal of this study is to understand
preferences for long-acting pre-exposure
prophylaxis (LA-PrEP) products for HIV
prevention among potential users and
providers, including product
characteristics and other service
delivery factors that may facilitate or
hinder future uptake of these products.
RTI will collaborate with CDC to
conduct a discrete choice experiment
(DCE) among providers and potential
users of LA-PrEP products to elicit their
preferences for characteristics of LAPrEP and delivery programs to
maximize uptake of LA-PrEP among
people in need of HIV prevention
methods. Results from this experiment
will be used to identify factors key to
adoption and implementation of each
product and increase implementation
efficiency by identifying strategies to
support decision making and address
potential use challenges early on.
The study design is a cross-sectional,
online survey comprised of a DCE and
additional questions to directly elicit
participant preferences and gather data
on socioeconomic, behavioral, and
attitudinal factors. DCE methods are
based on the principle that products or
services are evaluated through their
multiple features or ‘attributes,’ and that
an individual’s choice of a product or
service is a function of the utility of
each attribute option or ‘level.’
Attributes and their corresponding
levels are chosen to represent the
features of medications, devices, and
health care services that are relevant to
a health care decision.
The proposed information collection
will include two separate DCE surveys:
one for priority populations; and one for
clinicians. The survey uses an
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
experimental design to combine levels
from each attribute into hypothetical
product profiles and to pair profiles into
choice tasks. The experimental design
will be split into several blocks or
versions. Each equally sized block will
have 11 questions, with one question
being repeated across blocks.
Participants will be randomly assigned
to a block and will see only one block
when completing the survey instrument.
The study’s target population
includes clinical providers ages 18 and
older who prescribe PrEP and the
following priority population groups
who were selected because they have
the highest rates of HIV acquisition and
are in need for HIV prevention services.
To be eligible for the study, potential
participants in each of the priority
population groups must be 18 years of
age and older, living without HIV, and
meet the U.S. Public Health Service
(USPHS) indications for offering PrEP as
described in the 2021 USPHS Clinical
Practice Guidelines.
The study sample will be recruited
from cities with high numbers of annual
HIV diagnoses within the 57 priority
jurisdictions identified as part of the
Ending the HIV Epidemic (EHE)
initiative. Data collection will last
approximately six months. Participants
will be randomly assigned to a block
when they are sent their unique DCE
survey link and will only complete the
set of choice tasks in that block.
Throughout the study, we will closely
monitor recruitment and data collection
to ensure that screening criteria are
being met, key demographic groups are
adequately represented, and survey
completion rates are acceptable.
Participants will be reimbursed $20
upon completion of the DCE. A Visa gift
card will be sent electronically or
mailed via the postal system based on
the participant’s choice.
Participation is voluntary. For this
study, CDC intends to screen
approximately 9,200 participants and
enroll 1,840. CDC estimates that
approximately 15% of enrolled
participants will be removed from the
analysis due to fraud or incomplete
data, resulting in a final analysis sample
size of 1,600 participants. At 25 minutes
per survey and 10 minutes per
combined screener and consent, CDC
requests OMB approval for an estimated
2,282 annualized burden hours. There
are no costs to participants other than
their time.
E:\FR\FM\11OCN1.SGM
11OCN1
61329
Federal Register / Vol. 87, No. 195 / Tuesday, October 11, 2022 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average
burden per
response
(in hours)
Form name
Potential LA-PrEP users or Clients ................
Client Screening Survey & Consent Form .....
C4P Client DCE Survey .................................
Provider Screening Survey & Consent Form
8,050
1,610
1,150
1
1
1
10/60
25/60
10/60
C4P Provider DCE Survey .............................
230
1
20/60
Clinical providers who prescribe PrEP, in the
United States.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–22025 Filed 10–7–22; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Public Health
Laboratory Testing for Emerging
Antibiotic Resistance and Fungal
Threats. This collection will allow CDC
to partner with public health
laboratories and will help equip them to
detect and characterize isolates.
DATES: CDC must receive written
comments on or before December 12,
2022.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2022–
0119 by any of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
VerDate Sep<11>2014
17:37 Oct 07, 2022
Jkt 259001
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
FOR FURTHER INFORMATION CONTACT:
[60Day–23–1310; Docket No. CDC–2022–
0119]
ADDRESSES:
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments through
the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to the
address listed above.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
Type of respondent
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Public Health Laboratory Testing for
Emerging Antibiotic Resistance and
Fungal Threats (OMB Control No. 0920–
1310, Exp. 12/31/2023)—Revision—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
This state and local laboratory testing
capacity is being implemented by the
Department of Health and Human
Services (HHS), Centers for Disease
Control and Prevention (CDC) in
response to the Executive Order 13676
of September 18, 2014 (Attachment 1a),
the National Strategy of September 2014
(Attachment 1b) and to implement subobjective 2.1.1 of the National Action
Plan of March 2015 for Combating
Antibiotic Resistant Bacteria
(Attachment 1c). Data collected
throughout this network is also
authorized by Section 301 of the Public
Health Service Act (42 U.S.C. 241).
The Antibiotic Resistance Laboratory
Network (AR Lab Network) is made up
of jurisdictional public health
laboratories (i.e., all 50 states, five large
cities, and Puerto Rico). These public
health laboratories will be equipped to
detect and characterize isolates of
carbapenem-resistant Enterobacteriaceae
(CRE), carbapenem-resistant
Pseudomonas aeruginosa (CRPA), and
carbapenem-resistant Acinetobacter
baumannii (CRAB), as well as
carbapenemase-positive organisms
(CPOs) from colonization screening
swabs. These resistant bacteria are
E:\FR\FM\11OCN1.SGM
11OCN1
]]>Agencies
[Federal Register Volume 87, Number 195 (Tuesday, October 11, 2022)]
[Notices]
[Pages 61327-61329]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22025]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-23-22CX]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Preferences for Longer-Acting Preexposure
Prophylaxis (PrEP) Methods Among Persons in US Populations at Highest
Need: A Discrete Choice Experiment'' to the Office of Management and
Budget (OMB) for review and approval. CDC previously published a
``Proposed Data Collection Submitted for Public Comment and
Recommendations'' notice on March 2, 2022, to obtain comments from the
public and affected agencies. CDC did not receive comments related to
the previous notice. This notice serves to allow an additional 30 days
for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget
[[Page 61328]]
is particularly interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Preferences for Longer-Acting Preexposure Prophylaxis (PrEP)
Methods Among Persons in US Populations at Highest Need: A Discrete
Choice Experiment--New--National Center for HIV, Viral Hepatitis, STD,
and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
The 2022-2025 National HIV/AIDS Strategy includes a goal of
increasing PrEP coverage to 50% among persons with indications, from a
2017 baseline of 13.2%. Despite successes in development and scale up
of daily oral pre-exposure prophylaxis (PrEP) as a biomedical HIV
prevention product, studies consistently show obstacles to its uptake
and continuation. The Centers for Disease Control and Prevention (CDC)
and its partners must engage in early planning for the implementation
of longer-acting (LA)-PrEP agents to help achieve the U.S. Ending the
HIV Epidemic (EHE) goal of reducing incident HIV infections by 90% by
2030. Understanding providers' and priority populations' preferences
for different LA-PrEP agents and perceived advantages and disadvantages
of each product will be critical to estimating future uptake and market
share of the various products that are likely to come to market.
The goal of this study is to understand preferences for long-acting
pre-exposure prophylaxis (LA-PrEP) products for HIV prevention among
potential users and providers, including product characteristics and
other service delivery factors that may facilitate or hinder future
uptake of these products. RTI will collaborate with CDC to conduct a
discrete choice experiment (DCE) among providers and potential users of
LA-PrEP products to elicit their preferences for characteristics of LA-
PrEP and delivery programs to maximize uptake of LA-PrEP among people
in need of HIV prevention methods. Results from this experiment will be
used to identify factors key to adoption and implementation of each
product and increase implementation efficiency by identifying
strategies to support decision making and address potential use
challenges early on.
The study design is a cross-sectional, online survey comprised of a
DCE and additional questions to directly elicit participant preferences
and gather data on socioeconomic, behavioral, and attitudinal factors.
DCE methods are based on the principle that products or services are
evaluated through their multiple features or `attributes,' and that an
individual's choice of a product or service is a function of the
utility of each attribute option or `level.' Attributes and their
corresponding levels are chosen to represent the features of
medications, devices, and health care services that are relevant to a
health care decision.
The proposed information collection will include two separate DCE
surveys: one for priority populations; and one for clinicians. The
survey uses an experimental design to combine levels from each
attribute into hypothetical product profiles and to pair profiles into
choice tasks. The experimental design will be split into several blocks
or versions. Each equally sized block will have 11 questions, with one
question being repeated across blocks. Participants will be randomly
assigned to a block and will see only one block when completing the
survey instrument.
The study's target population includes clinical providers ages 18
and older who prescribe PrEP and the following priority population
groups who were selected because they have the highest rates of HIV
acquisition and are in need for HIV prevention services. To be eligible
for the study, potential participants in each of the priority
population groups must be 18 years of age and older, living without
HIV, and meet the U.S. Public Health Service (USPHS) indications for
offering PrEP as described in the 2021 USPHS Clinical Practice
Guidelines.
The study sample will be recruited from cities with high numbers of
annual HIV diagnoses within the 57 priority jurisdictions identified as
part of the Ending the HIV Epidemic (EHE) initiative. Data collection
will last approximately six months. Participants will be randomly
assigned to a block when they are sent their unique DCE survey link and
will only complete the set of choice tasks in that block. Throughout
the study, we will closely monitor recruitment and data collection to
ensure that screening criteria are being met, key demographic groups
are adequately represented, and survey completion rates are acceptable.
Participants will be reimbursed $20 upon completion of the DCE. A Visa
gift card will be sent electronically or mailed via the postal system
based on the participant's choice.
Participation is voluntary. For this study, CDC intends to screen
approximately 9,200 participants and enroll 1,840. CDC estimates that
approximately 15% of enrolled participants will be removed from the
analysis due to fraud or incomplete data, resulting in a final analysis
sample size of 1,600 participants. At 25 minutes per survey and 10
minutes per combined screener and consent, CDC requests OMB approval
for an estimated 2,282 annualized burden hours. There are no costs to
participants other than their time.
[[Page 61329]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Potential LA-PrEP users or Clients.... Client Screening Survey 8,050 1 10/60
& Consent Form.
C4P Client DCE Survey... 1,610 1 25/60
Clinical providers who prescribe PrEP, Provider Screening 1,150 1 10/60
in the United States. Survey & Consent Form.
C4P Provider DCE Survey. 230 1 20/60
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-22025 Filed 10-7-22; 8:45 am]
BILLING CODE 4163-18-P
